针对近视进展 (LAMP) 的低度氨酸的五年临床试验研究:第四阶段报告

Xiu Juan Zhang1, Yuzhou Zhang2, Benjamin H K Yip3

  • 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong; Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Shantou, China.

Ophthalmology
|March 17, 2024
PubMed
概括

持续低度的阿特罗宾在5年内有效控制近视. 大多数儿童在停止治疗后需要重新治疗,重新开始0.05%的类药物显示出与持续治疗相似的疗效.